Publicacions - Fundació Institut d'Investigació en Ciències de la

Piatkowska-Jakubas B, Skotnicki AB, Dombret H, Ribera JM, Piccaluga PP, Czerw T, Kyrcz-Krzemien S,
Holowiecki J.Status of minimal residual disease determines outcome of autologous hematopoietic stem
cell transplantation in adult acute lymphoblastic leukemia.
BONE MARROW TRANSPL 2010 Jun;45(6):1095-101. Epub 2009 Oct 26.
IF: 3,66
Hernández JM, Granada I, Solé F; Grupo Cooperativo Español de Citogenética Hematólogica From
conventional cytogenetics to microarrays.
Fifty years of Philadelphia chromosome
MED CLIN-BARCELONA 2010 Jun 29. [Epub ahead of print]
IF: 1,413
Juncà J, Moreno M, Mate JL, Milla F
Concomitant diagnosis of acute mieloide leucemia and chronic lymphoproliferative disorder with AA
amiloidosis as a final event
MED CLIN-BARCELONA 2010 Jun 19;135(3):136-7
IF: 1,413
M Batlle, Quesada MD, Moreno M, JM Ribera.
Outbreak of blastoschysomics spp infection in a haematology unit: study of 6 cases and finding of the
source of infection.
MED CLIN-BARCELONA 2010 Nov 13;135(14):672-4. Epub 2009 Jun 11.
IF: 1,413
MA. Sanz, P Montesinos, C Rayón, A Holowiecka, J de la Serna, G Milone, E de Lisa, S Brunet, V Rubio,
JM. Ribera, C Rivas, I Krsnik, J Bergua, J González, J Díaz-Mediavilla, R Rojas, F Manso, G Ossenkoppele,
JD González, B Lowenberg, on behalf of the PETHEMA and HOVON Groups
Risk-adapted Treatment of Acute Promyelocytic Leukemia Based on All-trans Retinoic Acid and
Anthracycline with Addition of Cytarabine in Consolidation Therapy for High-risk Patients: Further
Improvements in Treatment Outcome.
BLOOD 2010; 5137-46
IF: 10,558
Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R,García-Laraña J, Bengoechea E,
Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J,
Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva
B,Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF.
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction
therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and
prednisone in elderly patients with untreated multiple myeloma: a randomised trial
LANCET ONCOL 2010; 934-941
IF: 17,764
Mateos, MV; Cibeira, MT; Richardson, PG; Prosper, F; Oriol, A; de la Rubia, J; Lahuerta, JJ; Garcia-Sanz, R;
Extremera, S; Szyldergemajn, S; Corrado, C; Singer, H; Mitsiades, CS; Anderson, KC; Blade, J; San Miguel,
J
Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or
with Dexamethasone in Relapsed and Refractory Multiple Myeloma
CLIN CANCER RES 2010; jun-15, 16 (12) 3260-3269
IF: 7,338
Pàgina 64 de 148